A phase I, pharmacokinetic and pharmacodynamic study of nimotuzumab in Japanese patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 72, Issue 5, 2013, Pages 1063-1071

  Okamoto, Wataru ^a   Yoshino, Takayuki ^b   Takahashi, Toshiaki ^b   Okamoto, Isamu ^a   Ueda, Shinya ^a   Tsuya, Asuka ^b   Boku, Narikazu ^b   Nishio, Kazuto ^a   Fukuoka, Masahiro ^a   Yamamoto, Nobuyuki ^b   Nakagawa, Kazuhiko ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SHIZUOKA CANCER CENTER   (Japan)

Author keywords

EGFR; Nimotuzumab; Pharmacokinetics; Phase 1; Solid tumor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; NIMOTUZUMAB; PHARMACOLOGICAL BIOMARKER; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; MONOCLONAL ANTIBODY; TUMOR PROTEIN;

ACNE; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALLERGIC REACTION; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRADYCARDIA; CANCER GROWTH; CLINICAL ARTICLE; CONSTIPATION; CREATININE BLOOD LEVEL; DERMATITIS; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DYSPEPSIA; EGFR GENE; FATIGUE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENE DOSAGE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; HYPOMAGNESEMIA; HYPOTHERMIA; JAPANESE; LEUKOCYTE COUNT; LIMIT OF DETECTION; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; NAUSEA; NEUTROPHIL COUNT; PHASE 1 CLINICAL TRIAL; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RASH; SIDE EFFECT; SKIN BIOPSY; SKIN TOXICITY; SKIN TUMOR; SOLID TUMOR; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME; TUMOR BIOPSY; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECTS; DRUG ERUPTIONS; GENETICS; INCIDENCE; JAPAN; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; NEOPLASMS; PATHOPHYSIOLOGY; SKIN; TUMOR VOLUME;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ERUPTIONS; FEMALE; GENE DOSAGE; HUMANS; INCIDENCE; JAPAN; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SKIN; TUMOR BURDEN;

EID: 84887209168     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2277-8     Document Type: Article

References (27)

1. Pal SK, Pegram M (2005) Epidermal growth factor receptor and signal transduction: potential targets for anti-cancer therapy. Anticancer Drugs 16:483-494 (Pubitemid 40685732)
2. Rivera F, Vega-Villegas ME, Lopez-Brea MF, Marquez R (2008) Current situation of panitumumab, matuzumab, nimotuzumab and zalutumumab. Acta Oncol 47:9-19
3. Shawnta C, Aminah J (2010) STEPP for the EGFR inhibitor-induced rash - definitely a step in the right direction. Curr Oncol Rep 12:223-225
4. Racca P, Fanchini L, Caliendo V, Ritorto G, Evangelista W, Volpatto R, Milanesi E, Ciorba A, Paris M, Facilissimo I, Macripò G, Clerico M, Ciuffreda L (2008) Efficacy and skin toxicity management with cetuximab in metastatic colorectal cancer: outcomes from an oncologic/dermatologic cooperation. Clin Colorectal Cancer 7(1):48-54 (Pubitemid 351252451)
5. Pinto C, Barone CA, Girolomoni G, Russi EG, Merlano MC, Ferrari D, Maiello E (2011) Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy. Oncologist 16:228-238
6. Crombet T, Rak J, Pérez R, Viloria-Petit A (2002) Antiproliferative, antiangiogenic, and proapoptotic activity of H-R3: a humanized anti-EGFR antibody. Int J Cancer 101:567-575
7. Maceira M, Rengifo E, Cedeño M, Merino N, Parada AC (2004) Immunohistochemical recognition of the epidermal growth factor receptor by the h-R3 antibody in the skin of experimental animals. Appl Immunohistochem Mol Morphol 12(4):360-363 (Pubitemid 39602078)
8. Akashi Y, Okamoto I, Iwasa T, Yoshida T, Suzuki M, Hatashita E, Yamada Y, Satoh T, Fukuoka M, Ono K, Nakagawa K (2008) Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status. Br J Cancer 98:749-755 (Pubitemid 351272610)
9. Basavaraj C, Sierra P, Shivu J, Melarkode R, Montero E, Nair P (2010) Nimotuzumab with chemoradiation confers survival advantage in treatment naïve head and neck tumors overexpressing EGFR. Cancer Biol Ther 10(7):673-681
10. Rojo F, Gracias E, Villena N, Cruz T, Corominas JM, Corradino I, Cedeño M, Campas C, Osorio M, Iznaga N, Bellosillo B, Rovira A, Marsoni S, Gascon P, Serrano S, Sessa C, Crombet T, Albanell J (2010) Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: a SENDO foundation study. Clin Cancer Res 16(8):2474-2482
11. Crombet T, Osorio M, Cruz T, Roca C, Castillo R, Mon R, Iznaga-Escobar N, Figueredo R, Koropatnick J, Renginfo E, Ferna'ndez E, Alva'rez D, Torres O, Ramos M, Leonard I, Pérez R, Lage A (2004) Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 22(9):1646-1654 (Pubitemid 41079803)
12. Rodríguez MO, Rivero TC, Bahi RC, Muchuli CR, Bilbao MA, Vinageras EN, Alert J, Galainena JJ, Rodríguez E, Gracias E, Mulén B, Wilkinson B, Armas EL, Pérez K, Pineda I, Frómeta M, Leonard I, Mullens V, Viada C, Luaces P, Torres O, Iznaga N, Crombet T (2010) Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck cancer. Biol Ther 9(5):343-349
13. Crombet T, Figueredo J, Catala M, González S, Selva JC, Cruz TM, Toledo C, Silva S, Pestano Y, Ramos M, Leonard I, Torres O, Marinello P, Pérez R, Lage A (2006) Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3. Cancer Biol Ther 5(4):375-379
14. Talavera A, Friemann R, Gómez-Puerta S, Martinez-Fleites C, Garrido G, Rabasa A, López-Requena A, Pupo A, Johansen RF, Sa'nchez O, Krengel U, Morenoet E (2009) Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. Cancer Res 69(14):5851-5859
15. Garrido G, Tikhomirov IA, Rabasa A, Yang E, Gracia E, Iznaga N, Fernández LE, Crombet T, Kerbel RS, Pérez R (2011) Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile. Cancer Biol Ther 11(4):373-382
16. You B, Brade A, Magalhaes JM, Siu LL, Oza A, Lovell S, Wang L, Hedley DW, Nicacio LV, Chen EX (2011) A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies. Invest New Drugs 29(5):996-1003
17. Crombet T, Torres L, Neninger E, Catala' M, Solano ME, Perera A, Torres O, Iznaga N, Torres F, Pérez R, Lage A (2003) Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, patients with advanced epithelial-derived cancer. J Immunother 26(2):139-148 (Pubitemid 36292784)
18. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, Ludovini V, Magrini E, Gregorc V, Doglioni C, Sidoni A, Tonato M, Franklin WA, Crino L, Bunn PA Jr, Varella-Garcia M (2005) Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. Nat Cancer Inst 97(9):643-655 (Pubitemid 40812628)
19. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, Lorimer I, Zhang T, Liu N, Daneshmand M, Marrano P, Santos GC, Lagarde A, Richardson F, Seymour L, Whitehead M, Ding K, Pater J, Shepherd FA (2005) Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 353(2):133-144 (Pubitemid 41058345)
20. Kim YH, Sasaki Y, Lee KH, Rha SY, Park S, Boku N, Komatsu Y, Kim T, Kim S, Sakata Y (2011) Randomized phase II study of nimotuzumab, an anti-EGFR antibody, plus irinotecan in patients with 5-fluorouracil-based regimen-refractory advanced or recurrent gastric cancer in Korea and Japan: preliminary results. ASCO GI poster session abstract 87
21. Knijn N, Tol J, Koopman M, Werter MJBP, Imholz ALT, Valster FAA, Mol L, Vincent AD, Teerenstra S, Punt CJA (2011) The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients. Eur J Cancer 47:369-374
22. Bodnar L, Wcislo G, Gasowska-Bodnar A, Synowiec A, Szarlej-Wcisło K, Szczylika C (2008) Renal protection with magnesium subcarbonate and magnesium sulphate in patients with epithelial ovarian cancer after cisplatin and paclitaxel chemotherapy: a randomised phase II study. Eur J Cancer 44:2608-2614
23. Cao Y, Liao C, Tan A, Liu L, Gao F (2010) Meta-analysis of incidence and risk of hypomagnesemia with cetuximab for advanced cancer. Chemotherapy 56:459-465
24. Fernandez A, Spitzer E, Perez R, Boehmer FD, Eckert K, Zschiesche W, Grosse R (1992) A new monoclonal antibody for detection of EGF-receptors in western blots and paraffin-embedded tissue sections. J Cel Biochem 49(2):157-165
25. Hirsch FR, Herbst RS, Olsen C, Chansky K, Crowley J, Kelly K, Franklin WA, Bunn PA Jr, Varella-Garcia M, Gandara DR (2008) Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol 26(20):3351-3357
26. Boland WK, Bebb G (2009) Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity. Expert Opin Biol Ther 9(9):1-7
27. Kimura M, Tsuda H, Morita D, Ichikura T, Ogata S, Aida S, Yoshizumi Y, Maehara T, Mochizuki H, Matsubara O (2004) A proposal for diagnostically meaningful criteria to classify increased epidermal growth factor receptor and c-erbB-2 gene copy numbers in gastric carcinoma, based on correlation of fluorescence in situ hybridization and immunohistochemical measurements. Virchows Arch 445(3):255-262 (Pubitemid 39286893)